Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal for immunotherapy of cancer Ročník 7; číslo 1; s. 181 - 5
Hlavní autori:	Glutsch, Valerie, Grän, Franziska, Weber, Judith, Gesierich, Anja, Goebeler, Matthias, Schilling, Bastian
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 12.07.2019 BioMed Central Ltd BMJ Publishing Group LTD BMJ Publishing Group
Predmet:	Abdomen Acute kidney failure Aged Antibodies Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Cancer Cancer metastasis Case Report Case Reports CAT scans Consent Creatinine Dehydrogenases Development and progression Disease Diuretics Dosage and administration Drug Substitution Drug therapy Edema Funding Humans Immune checkpoint inhibitors Immune-related adverse event Immunology Immunotherapy Ipilimumab Ipilimumab - administration & dosage Kidney diseases Kidney failure Kidney Function Tests Kidneys Lymphatic system Male Medical imaging Medical research Medicine Medicine & Public Health Melanoma Melanoma - complications Melanoma - diagnosis Melanoma - drug therapy Metastasis Microscopy Minimal change disease Molecular Targeted Therapy - adverse effects Monoclonal antibodies Nephritis Nephrotic syndrome Nephrotic Syndrome - diagnosis Nephrotic Syndrome - etiology Nivolumab Nivolumab - administration & dosage Oncology Oral drugs Patients PD-1 Pharmaceuticals Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Skin cancer Targeted cancer therapy Treatment Outcome Tumors Urine Minimal change disease Immune-related adverse event PD-1 Ipilimumab Nivolumab
ISSN:	2051-1426, 2051-1426
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!